Table 3.
Treatment outcomes of each patient
| Patient no.a | Age (years) |
Regimen and embolic material | Tumor size (mm) | Regression rate (%) | Progression rate | Complications | |
|---|---|---|---|---|---|---|---|
| Before TACE | After TACE | ||||||
| 1 | 23 | b CDDP [25 mg]+5 FU [250 mg]+EPI [20 mg], CDDP-HepaSphere (50–100 µm) [ 12.0 mg] | 102 | 76 | 25.5 | SD | Nausea (Grade 1), |
| 2 | 49 | CDDP [75 mg]+5 FU [400 mg], 5-FU-HepaSphere (50–100 µm) [2.75 mg] | 52 | 44 | 15.4 | SD | Nausea (Grade 1) |
| 3 | 43 | CDDP [25 mg]+5 FU [250 mg], CDDP-HepaSphere (30–60 µm) [10.5 mg] | 90 | 79 | 12.2 | SD | − |
| 4 | 59 | CDDP [30 mg]+5 FU [250 mg], CDDP-HepaSphere (50–100 µm) [0.25 mg] | 64 | 53 | 17.2 | SD | − |
| 5 | 72 | CDDP [25 mg]+5 FU [250 mg]+MMC [4 mg], CDDP-HepaSphere (50–100 µm) [5.0 mg] | 77 | 68 | 11.7 | SD | WBC and platelet decreased (Grade 3) |
| 6 | 68 | CDDP [25 mg]+5 FU [500 mg]+EPI [10 mg], CDDP-HepaSphere (50–100 µm) [21.0 mg] | 91 | 83 | 8.8 | SD | − |
| 7 | 41 | CDDP [50 mg], B.HepaSphere (100–150 µm) [4.75 mg] | 110 | 104 | 5.5 | SD | Pain (Grade 1) |
| 8 | 67 | CDDP [50 mg]+5 FU [500 mg], B.HepaSphere (50–100 µm) [6.5 mg] | 56 | 55 | 1.8 | SD | − |
| 9 | 63 | b* CDDP [50 mg], B.HepaSphere (50–100 µm) [5.5 mg] | 42 | 24 | 42.9 | PR | Anaemia (Grade 3) |
| 10 | 38 | CDDP [100 mg]+5 FU [500 mg], B.HepaSphere (100–150 µm) [23.0 mg] | 104 | 92 | 11.5 | SD | Pain (Grade 1) |
| 11 | 57 | CDDP [50 mg]+5 FU [500 mg], B.HepaSphere (50–100 µm) [1.5 mg] | 66 | 53 | 19.7 | SD | Nausea
(Grade 1) Pain (Grade 1) |
| 12 | 68 | CDDP [50 mg]+5 FU [500 mg], B.HepaSphere (100–150 µm) [2.5 mg] | 29 | 24 | 17.2 | SD | − |
| 13 | 68 | CDDP [20 mg]+5 FU [250 mg] , B.HepaSphere (50–100 µm) [0.5 mg] | 24 | 21 | 12.5 | SD | − |
| 14 | 63 | cCDDP [50 mg]+5 FU [500 mg], B.HepaSphere (100–150 µm) [2.5 mg] | 49 | 41 | 16.3 | SD | − |
B.HepaSphere, bland HepaSphere microspheres;CDDP, cisplatin; CDDP-HepaSphere, cisplatin-loaded HepaSphere microspheres; EPI, epirubicin; 5-FU, fluorouracil; 5-FU-HepaSphere, 5-FU-loaded HepaSphere microspheres; MMC, mitomycin C;TACE, transcatheter arterial chemoembolization.
For patients with multiple tumors, tumor size was calculated as the sum of the tumor diameters.
Patient numbers do not match those of Figure 4.
Seventy % of the anticancer drug and 7 mg of HepaSphere was targeted to primary HCC; therefore, the actual dose administered to the lung was CDDP [7.5 mg]+5 FU [75 mg]+EPI [6 mg], CDDP-HepaSphere (50–100 µm) [ 5.0 mg].
A half of the anticancer drug and 3.5 mg of HepaSphere was targeted to primary HCC; therefore, the actual dose administered to the lung was CDDP [25 mg], B.HepaSphere (50–100 µm) [2.0 mg].